

Editor: David Lowe  
Assistant Editor: Helen Holzel  
Technical Editor: Andrea Horgan  
Editorial Assistant: Mavis Burrell  
BMA House, Tavistock Square, London WC1H 9JR; Tel 0171 383 6209

### EDITORIAL BOARD

AL Appleton	JD Davies	JS Lilleyman	RS Pereira	D Tarin
CC Bird	FV Flynn	AJ Malcolm	GL Ridgway	DR Turner
AW Boylston	DJ Goldie	JH McCarthy	C Roberts	DA Winfield
D Burnett	JHE Hayek	RN Peel	DN Slater	B Woodcock
J Crocker	FD Lee	MD Penney	RC Spencer	Editor, <i>BMJ</i>

### Former Editors

AG Signy 1944-72 HEM Kay 1972-80 G Slavin 1978-88 J Lilleyman 1986-92

### Association of Clinical Pathologists

President: Dr WR Timperley; President-Elect: Dr PM Emerson; Vice-Presidents: Dr PJ Fitzpatrick, Dr JD Davies; Chairman of Council: Dr DM Harris; Honorary Secretary: Dr AJ Malcolm; Honorary Treasurer: Dr AC Ames; General Secretary: Mrs JS Turner, 221 Preston Road, Brighton BN1 6SA; Tel: (01273)561188; Fax: (01273) 541227

### Information for Authors

**Papers should be sent in duplicate to the Editors,** *Journal of Clinical Pathology*, BMJ Publishing Group, BMA House, Tavistock Square, London WC1H 9JR. Telephone numbers: 0171 383 6209/6154. Fax number: 0171 383 6668. They should be typewritten with double spacing on one side of the paper only. The names of the authors with initials or one forename should be followed by the name of the institution where the work was performed. An indication of the position held by each author must be given in an accompanying letter to the Editors, and this should include the signatures of all authors on papers with joint authorship. Guidelines on authorship are detailed in *J Clin Pathol* 1986;39:110. Results should not be shown as both tables and graphs, and histograms should not be used where tabular information would be more appropriate.

**ARTICLES** Papers should usually be no more than 2000 words long and should report original research of relevance to the understanding and practice of clinical pathology. They should be written in the standard format with a structured abstract. The abstract should contain the headings *Aims, Methods, Results and Conclusions* and be no more than 250 words long. The body of the paper should have separate sections for the introduction, the methods and the results, and the discussion. If statistics are used the methods and confidence intervals should be stated. Authors are urged to seek expert advice if in doubt. Revised manuscripts should be submitted as hard copy and on disk. Detailed instructions will be sent to authors on invitation to revise. Occasional Articles have a less rigid format, being 1500-2000 words in length. They are usually invited by the editors, though unsolicited submissions will be considered. Single case reports and brief papers (such as those describing negative findings) will usually be considered only as Short Reports. The format for these is an unstructured 150 word summary, up to 1500 words of text, up to two tables or figures (or one of each) and no more than 10 references. Letters to the Editor should normally refer to previously published papers or make some point about the practice of pathology. They are not intended to be a vehicle for the presentation of new data unrelated to earlier Journal articles.

**ACKNOWLEDGMENT OF RECEIPT** A stamped addressed post-card should be enclosed for return to the author as acknowledgment of receipt of the manuscript. Overseas authors should enclose international reply paid coupons.

**ETHICS** The critical assessment of papers submitted will include ethical considerations.

**ILLUSTRATIONS** Diagrams should be reproduced photographically. The legends for illustrations should be typed with double spacing on a separate sheet. Photographs and photomicrographs must be of high quality in full tonal scale on glossy paper, and unmounted. Only salient detail should be included. Areas without tissue ("background") should be as near white as possible. The width of illustrations should be 6.7 cm, 10.2 cm,

13.7 cm or, in exceptional circumstances, 17.4 cm, to fit the column layout of the Journal. Colour reproduction is welcomed and is subsidised by the Journal; for details of costs to the author please contact the Journal office.

**ABBREVIATIONS** Abbreviations must be spelt out on first use or be accompanied by explanation in the text. The use of non-standard abbreviations and acronyms should be avoided.

Symbols and abbreviations should be in the Vancouver style.

**UNITS** All measurements should be given in SI units.

**REFERENCES** The references must be given in the Vancouver style.

**REPRINTS** These may be ordered when the proof is returned. Prices for large numbers of reprints available on request.

**NOTICE TO ADVERTISERS** Applications for advertisement space and for rates should be addressed to the Advertisement Manager, *Journal of Clinical Pathology*, BMJ Publishing Group, BMA House, Tavistock Square, London WC1H 9JR.

The *Journal of Clinical Pathology* is published monthly. The annual subscription rates (including *Clinical Molecular Pathology*) are £265.00; USA \$418.00. Orders should be sent to The Subscription Manager, *Journal of Clinical Pathology*, BMJ Publishing Group, BMA House, Tavistock Square, London WC1H 9JR. Subscribers may pay for their subscriptions by Access, Visa, or American Express, by quoting on their order the credit or charge card preferred, together with the appropriate personal account number and expiry date of the card. Orders can also be placed with any leading subscription agent or bookseller. (For the convenience of readers in the USA subscription orders, with or without payment, may also be sent to the *British Medical Journal*, Box 408, Franklin, MA 02038, USA. All enquiries, however, must be addressed to the publisher in London.) All enquiries regarding air mail rates and single copies already published should be addressed to the publisher in London.

**COPYRIGHT** © 1995 *Journal of Clinical Pathology*. This publication is copyright under the Berne Convention and the International Copyright Convention. All rights reserved. Apart from any relaxations permitted under national copyright laws, no part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means without the prior permission of the copyright owners. Permission is not, however, required to copy abstracts of papers or of articles on condition that a full reference to the source is shown. Multiple copying of the contents of the publication without permission is always illegal.

Second class postage paid, at Rahway N. J. Postmaster to send address changes to: Journal of Clinical Pathology c/o Mercury Airfreight International Ltd. Inc., 2323 Randolph Avenue, Avenel, NJ 07001, USA.  
ISSN 0021-9746.

Cover illustration:  
*Helicobacter pylori* in gastric mucosa. Cresol fast red stain.  
Supplied by Dr Roger Feakins.

Published by BMJ  
Publishing Group and  
printed in England by  
Latimer Trend & Co.,  
Plymouth

### CD34 immunoperoxidase staining for the diagnosis of myelodysplastic syndromes and chronic myeloid leukaemia

Horny *et al*<sup>1</sup> recently reported that immunoperoxidase staining of bone marrow biopsy specimens with the CD34/QBEND10 monoclonal antibody can be used to separate the myelodysplastic syndromes RAEB and RAEB-T from the RA and RARS subtypes. This report has now confirmed our previous findings that CD34/QBEND10 is a useful reagent for the study of conventionally processed, paraffin wax embedded bone marrow biopsy specimens.<sup>2</sup> We have recently studied bone marrow biopsy specimens from 58 cases of primary myelodysplastic syndromes addressing the diagnostic value of CD34 staining in these conditions.<sup>3</sup> We found that CD34 immunostaining can help in the detection of the increased number of blasts associated with the RAEB and RAEB-T subtypes. In addition, our study showed that QBEND10 represents a powerful prognostic tool for predicting survival and outcome in myelodysplastic syndromes. In primary RAEB cases median survival was 41 months in those with less than 1% CD34+ cells, and 29 months in those with more than 1% CD34+ cells ( $p < 0.05$ ).<sup>3</sup> Similar results were obtained in cases of therapy related myelodysplastic syndromes: CD34+ cases had a mean survival of 10 months compared with 43 months for the CD34- cases ( $p < 0.0005$ ).<sup>4</sup>

The authors also suggest the potential usefulness of CD34 staining for identifying patients in the accelerated phase of chronic myeloid leukaemia. Our recently published study of 59 bone marrow biopsy specimens representing the three phases (stable, accelerated and blastic) of chronic myeloid leukaemia has indeed confirmed the finding of a statistically higher CD34 value in the two aggressive phases of this disease compared with the stable phase.<sup>5</sup>

Taken together, these data and those from Horny *et al*<sup>1</sup> show that QBEND10 is a very useful reagent for the study of routinely processed bone marrow biopsy specimens and may provide useful diagnostic and prognostic information in myelodysplastic syndromes and myeloproliferative disorders. This type of approach may be especially valuable when a paraffin wax embedded specimen is the only material available for immunophenotyping.

A ORAZI

Associate Professor of Pathology,  
Director, Section of Immunohistochemistry,  
Department of Pathology and Laboratory Medicine,  
University Hospital 4430,  
Indiana University Medical Center,  
550 North University Blvd,  
Indianapolis,  
Indiana 46202-5283, USA

- Horny HP, Wehrmann M, Schlicker HUH, Eichstaedt A, Clemens MR, Kaiserling E. QBEND10 for the diagnosis of myelodysplastic syndromes in routinely processed bone marrow biopsy specimens. *J Clin Pathol* 1995;48:291-4.
- Soligo D, Delia D, Oriani A, Cattoretti G, Orazi A, Bertoli V, *et al*. Identification of CD34+ cells in normal and pathologic bone marrow biopsies by QBEND10 monoclonal antibody. *Leukemia* 1991;5:1026-30.
- Soligo D, Oriani A, Annaloro C, Cortelezzi A, Calori R, Pozzoli E, *et al*. CD34 immunohistochemistry of bone marrow biopsies: prognostic significance in primary myelodysplastic syndromes. *Am J Hematol* 1994;46:9-17.
- Orazi A, Cattoretti G, Soligo D, Luksch R, Lambertenghi Delilieri G. Therapy-related myelodysplastic syndromes: FAB classification, bone marrow histology, and immunohistology in the prognostic assessment. *Leukemia* 1993;7:838-47.
- Orazi A, Neiman RS, Cuaing H, Heerema N, John K. CD34 immunostaining of bone marrow biopsy specimens is a reliable way to classify the phases of chronic myeloid leukaemia. *Am J Clin Pathol* 1994;101:426-8.

## Book review

If you wish to order or require further information regarding the titles reviewed here, please write to or telephone the BMJ Bookshop, PO Box 295, London WC1H 9JR. Tel 071 383 6244. Fax 071 383 6662. Books are supplied post free in the UK and for British Forces Posted Overseas addresses. Overseas customers should add 15% for postage and packing. Payment can be made by cheque in sterling drawn on a UK bank or by credit card (Mastercard, Visa, or American Express) stating card number, expiry date, and full name. (The price and availability are occasionally subject to revision by the Publishers.)

**Diseases of the Bronchioles.** Ed GR Epler. (Pp 462; £132.50.) Raven Press. 1993. ISBN 0-7817-0123-6.

This textbook deals in depth with what is a very highly specialised subject, bronchiolar pathology. The editor is an established expert in pulmonary disease and has asked many experts, particularly clinicians, to contribute to the book. The book provides up to the minute information on what is known about bronchiolar disease. It concentrates on infections, smoking, occupational disease, obliterative bronchiolitis, and bronchiolitis organising pneumonia (BOOP), the last two conditions which in the past have been lumped together but which this book clearly separates and clarifies as being different entities with vastly different prognoses. There are excellent chapters on history, anatomy, imaging, pathology, and the various causes of bronchiolar disease. The clinicians' viewpoint is emphasised. However, the penalty of being a multi-author book is that there is discontinuity and a lot of repetition. The editor should have exercised more control over this aspect of the book which makes it very annoying and boring at times when the same references and observations are made by several authors. While not of general interest I would recommend it to pathologists interested in pulmonary pathology as it deals in great depth with what has been pathologically and clinically a very confusing and poorly illustrated area of lung disease in the past.

M N SHEPPARD

## Notices

### Texas Society of Pathologists

75 Years Young

presents

### Pathology: Past, Present and Future

Diamond Jubilee Celebration

February 1-4 1996

For further information, please contact: Paula Rigling, Texas Society of Pathologists, 401 West 15th Street, Austin, Texas 78701-1680, USA.

### Lung pathology course

October 31 to November 3 1995

### National Heart and Lung Institute

For further information, please contact: Professor B Corrin, Histopathology, Royal Brompton Hospital, London SW3 6NP (fax: 0171 351 8435).

First Announcement

### 5th International Congress on Trace Elements in Medicine and Biology

presents

### Therapeutic Uses of Trace Elements

February 4-7 1996

Main topics include: Therapeutic forms of trace elements; large epidemiological and intervention studies related to trace elements; trace element supplementation of population groups of differing ages; and trace elements, bone physiology and bone diseases, among others.

For further information, please contact: Madame A Alcaraz, Laboratoire de Biochimie C, CHURG, B.P. 217, F-38043 Grenoble Cedex 9, France (tel: (33) 76 76 54 84; fax: (33) 76 76 56 64).

### Postgraduate course

### Current concepts in surgical pathology

November 6-10 1995

The Department of Pathology, Massachusetts General Hospital, Harvard Medical School, will present a postgraduate course in Surgical Pathology under the direction of Drs Nancy L Harris, Robert H Young and Eugene J Mark.

This course is designed for pathologists at resident and practitioner levels. It will provide an in-depth review of diagnostic surgical pathology with emphasis on morphologic features, newly recognised entities, and new techniques, presented by the faculty of the Department of Pathology, Massachusetts General Hospital. Instruction will be primarily by lecture, but will also include discussion periods. Each participant will receive a comprehensive course syllabus.

The course has Category 1 accreditation for approximately 35 hours CME credit by the American Medical Association. The fee for the course is \$825.00 (£522.00) (residents and fellows \$610.00 (£386.00)).

For further information, please contact: Department of Continuing Education, Harvard Medical School, 25 Shattuck Street, Boston, MA 02115, USA (tel: (617) 432-1525).

### Correction

Microscopic thymoma and myasthenia gravis (*J Clin Pathol* 1995;48:682-683). The authors apologise for the errors which appeared in the Pathological findings section of their report. In the last line of the first paragraph, 272 x 71 mm should read 272 x 71 µm. In the final paragraph, 107 mm (range 41-237 mm) should read 107 µm (range 41-237 µm).